Literature DB >> 25088280

Ageing in people with Prader-Willi syndrome: mortality in the UK population cohort and morbidity in an older sample of adults.

J E Whittington1, A J Holland1, T Webb1.   

Abstract

BACKGROUND: The past two decades have seen a great improvement in the care of people with Prader-Willi syndrome (PWS), particularly with regard to control of diet and behaviour management. Has this affected mortality rates or thrown up new issues regarding premature ageing or dementia? We investigated two aspects of ageing in people with PWS: (1) an estimate of mortality over 9 years in a cohort of people with PWS, originally recruited in 1998-2000; and (2) premature ageing or dementia in people aged ⩾40 years.
METHOD: (1) A follow-up of the population-based 1998-2000 cohort to investigate the subsequent mortality rate; and (2) the recruitment and structured assessment of all members of the Prader-Willi Syndrome Association UK (PWSA-UK) aged ⩾40 years who agreed to participate.
RESULTS: Follow-up of the population-based 1998-2000 cohort gave a mortality rate of at least 7/62 over 9 years (1.25% per annum; 20 untraced), age at death was between 13 and 59 years. Twenty-six members of the PWSA-UK aged ⩾40 years were recruited, 18 of whom had a genetic diagnosis (gd) of PWS. Twenty-two (14 gd) showed no evidence of dementia. Four, with possible symptoms, are described in more detail; all are female, of maternal uniparental disomy (mUPD) genetic subtype, or have a disomic region, and all have a long history of psychotic illness.
CONCLUSIONS: The mortality rate in people with PWS seems to be declining. The subgroup of people with PWS due to UPD or disomic region with female gender and a history of psychosis may be at risk of early onset dementia.

Entities:  

Keywords:  Alzheimer's disease; Prader–Willi syndrome; dementia; genetic subtype; mortality; psychosis

Mesh:

Year:  2014        PMID: 25088280     DOI: 10.1017/S0033291714001755

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  8 in total

Review 1.  Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.

Authors:  Krystal A Irizarry; Mark Miller; Michael Freemark; Andrea M Haqq
Journal:  Adv Pediatr       Date:  2016-08

2.  Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial.

Authors:  R J Kuppens; E F Mahabier; N E Bakker; E P C Siemensma; S H Donze; A C S Hokken-Koelega
Journal:  Orphanet J Rare Dis       Date:  2016-11-16       Impact factor: 4.123

3.  Survival trends from the Prader-Willi Syndrome Association (USA) 40-year mortality survey.

Authors:  Ann M Manzardo; James Loker; Janalee Heinemann; Carolyn Loker; Merlin G Butler
Journal:  Genet Med       Date:  2017-07-06       Impact factor: 8.822

Review 4.  Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome.

Authors:  Régis Afonso Costa; Igor Ribeiro Ferreira; Hiago Azevedo Cintra; Leonardo Henrique Ferreira Gomes; Letícia da Cunha Guida
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-13       Impact factor: 5.555

5.  Evidence for Accelerated Biological Aging in Young Adults with Prader-Willi Syndrome.

Authors:  Stephany H Donze; Veryan Codd; Layla Damen; Wesley J Goedegebuure; Matthew Denniff; Nilesh J Samani; Janiëlle A E M van der Velden; Anita C S Hokken-Koelega
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

6.  Family Matters: Trauma and Quality of Life in Family Members of Individuals With Prader-Willi Syndrome.

Authors:  Anja Bos-Roubos; Ellen Wingbermühle; Anneloes Biert; Laura de Graaff; Jos Egger
Journal:  Front Psychiatry       Date:  2022-06-28       Impact factor: 5.435

Review 7.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

8.  Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader-Willi Syndrome: A Case Report.

Authors:  Yukio Horikawa; Mayumi Enya; Makie Komagata; Ken-Ichi Hashimoto; Masayo Kagami; Maki Fukami; Jun Takeda
Journal:  Diabetes Ther       Date:  2018-01-15       Impact factor: 2.945

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.